BridgeBio Oncology Therapeutics (BBOT) vs Rocket Pharmaceuticals (RCKT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Rocket Pharmaceuticals (RCKT) has outperformed BridgeBio Oncology Therapeutics (BBOT) over the past year, losing 19.3% versus a loss of 71.6%. Rocket Pharmaceuticals is the larger company by market cap ($288.7 million vs $274.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBOT | RCKT |
|---|---|---|
| Share price | $3.42 | $2.63 |
| Market cap | $274.20M | $288.71M |
| 1-day change | -0.58% | +3.75% |
| YTD return | -72.68% | -27.78% |
| 1-year return | -71.56% | -19.27% |
| 5-year return | — | -90.58% |
| EPS (TTM) | $-0.07 | $-0.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.87 | $5.45 |
| 52-week low | $3.27 | $2.42 |
| Distance from 52-week high | -77.00% | -51.74% |
| Analyst consensus | none | buy |
| Avg. price target upside | +617.84% | +223.19% |
| Average volume | 468.94K | 1.66M |
| Shares outstanding | 80.17M | 109.77M |
| Employees | 88 | 202 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RCKT has outperformed BBOT by 52.3 percentage points over the past year.
About BridgeBio Oncology Therapeutics
BBOT stock →BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
About Rocket Pharmaceuticals
RCKT stock →Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 202 employees
BBOT vs RCKT FAQ
Which is bigger, BridgeBio Oncology Therapeutics or Rocket Pharmaceuticals?
Rocket Pharmaceuticals (RCKT) is larger, with a market capitalization of $288.71M compared with $274.20M for BridgeBio Oncology Therapeutics (BBOT).
Which stock has performed better over the past year, BBOT or RCKT?
RCKT returned -19.27% over the past 12 months, compared with -71.56% for BBOT (price return, excluding dividends). Past performance does not predict future results.
Are BridgeBio Oncology Therapeutics and Rocket Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.